XEFO Special Precautions
In the following conditions Xefo should be administered only after careful risk-benefit asseseement. Gastrointestinal ulceration and bleeding in medical history; discontinue treatment if peptic ulceration and/or gastrointestinal bleeding occurs.
Renal impairment: mild (serum creatinine 150 to 300 micromol/l), monitor at one to two month intervals.
Blood coagulation disorders; careful monitoring recommended.
Liver disease (eg, cirrhosis); regular monitoring recommended. Long-term treatment (longer than three months), monitor haemoglobin, creatinine and liver enzymes regularly.
Elderly; monitor renal and hepatic function in patients over 65 years. Hypertension and/or obesity; monitor blood pressure and renal function. Monitor renal function in patients who are to undergo major surgery, with stressed renal function (eg, as a result of significant blood loss or severe dehydration), with cardiac failure, receiving concomitant treatment with diuretics or with drugs suspected or known to be able to cause kidney damage.
XEFO Adverse Reactions
Most commonly (frqency 1 to 10%): abdominal pain, diarrhoea, dizziness, dyspepsia, headache, nausea, vomiting.
Rarely (frequency <1%): constipation, dysphagia, dry mouth, flatulence, gastritis, gastro-oesophageal reflux, peptic ulceration and/or gastrointestinal bleeding, stomatitis, haemorrhoidal bleeding, liver function abnormalities, alopecia, dermatitis, pruritus, increased sweating, micturition disorder, oedema, leg cramps paraesthesia, tremor, conjunctivitis, vision disorder, tinnitus, taste perversion, allergic reactions, anaemia, thrombocytopenia, increased bleeding time, ecchymoses, hypertension, palpitations, tachycardia, agitation, depression, insomnia, solnolence, alteration in appetite, weight changes, mylagia, malaise, weakness.